Tom Wilemon

July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

By Tom Wilemon
July 18, 2019

Hooker to lead National Society of Genetic Counselors

Gillian Hooker, PhD, ScM, president-elect of the National Society of Genetic Counselors, will lead the organization at a pivotal time when she takes over as president Jan. 1, 2020.

By Tom Wilemon
Jeffrey Rathmell, PhD, directs the Vanderbilt Center for Immunobiology.
July 18, 2019

Center for Immunobiology grows, bolsters program

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.

By Tom Wilemon
lungs
June 27, 2019

Health disparity for black people exists within lung screening guidelines

By Tom Wilemon
June 26, 2019

Biomarkers of DNA methylation can be a predictor of breast cancer risk

Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk.

By Tom Wilemon
June 18, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

By Tom Wilemon
June 13, 2019

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
By Tom Wilemon
June 13, 2019

Eng named to GI cancer leadership position at VICC

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
By Tom Wilemon
June 13, 2019

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
By Tom Wilemon
June 6, 2019

Immunotherapy helping 87-year-old man stay on the job

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.
By Tom Wilemon
May 3, 2019

Bioimpedance spectroscopy better than tape measure for identifying lymphedema risk

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema.
By Tom Wilemon
April 22, 2019

Cancer Center’s annual scientific retreat set for May 1

The varying roles that signaling molecules play in progression of cancer is the focus of the Vanderbilt-Ingram Cancer Center 20th Annual Scientific Retreat when some of the nation’s top experts will speak about “Signal Transduction in Cancer Initiation, Progression and Treatment.”
By Tom Wilemon
1 … 21 22 23 24 25 … 37